Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
https://www.google.co.uk/amp/s/www.labiotech.eu/interviews/futura-medical-angela-hildreth/amp/
Thank you Jet, my predictions are purely on past experience with FUM and other similar companies.
I could be wrong, but I did and still do see this at between 50p -£1 prior to results. Even if some funds are raised...at £1 it will have a market cap of ~200m, I have seen this many times for this kind of company approaching ph3 readout. But somewhere in between and I will be happy, and 50p should be minimum!!!
GL
Zwat, are you for real?
IF the results are good, not just for the 1st phase 3 but also the 2nd, yes there is no reason why this will not be taken over/ licensing deal with an overall value to FUM of a billion, or more.
Look we don’t know how the board plan to handle good results e.g. sell it/ TO or licensing deal quickly, or take it to the 2nd phase 3 and gain more value.
What you are saying is that if this product achieves good results through phase 3, gets the green light for market, also the ability to create sales of close to a billion/ annum from Prescription & OTC, also possibly being far superior to viagra, what you think that FUM will be valued at far less if the above pans out???
A product that has sales of only 60-100million can be worth a billion in a take over.
The way licensing deals are structured, there are upfront payments with future milestones, that if reached will release huge payments to the company. There are many many examples of this, google them.
No one can tell you what the results will be, but between now and then this should double from here. On results day the share price could 10bag or 10bomb! Lol. DEPENDANT on the results.
And regarding finance, they said results will effect the financing outcome. But let’s say they do raise funds now, likely will be a private placement, we will only know about it once done and it will be at a small discount to whatever the share price is, it will then continue north for results.
If they wait for results and they are good, they will have investors and companies throwing money at them at multiples of today.
GL
share price was going to bomb to below 10p or the teens, it would be there already guys. It wouldn’t take much to drop this, MM/big holders or the likes of Lombard offloading.
It’s not happened, why? If there was so much concern of funding, it would have bombed already.
Every aim company that I have ever seen embark on the lit first ph3 trail, are in the same position, they raise money for the first, then they raise more for the second. If FUM raise money now it will be around the level the share price is at with a little discount. Or they will wait for results and like they said, the fund raise will be impacted by the outcome of the results. If results are good they will be raising at multiples of today’s price.
With only 2 months to go, this will continue north at some point, at the moment it is trading side ways, consolidating. Something will come along to trigger the next leg up.
I stand by my prediction over the past year, this will have a market cap prior to results days of minimum 100m, up to anywhere near 200m. This is dependant on the awareness of the share in the general public unfortunately.
Risk vs reward is crazy because if results are good this will disrupt the market massively, and big players will not want that if they are not part of it. If results are good you are talking about a billion dollar take out.
While it has a good chance of success, like any drug in trail no one can be certain of outcome, as even if drug works, which has been proven, no one can estimate the placebo result.
Buy and hold what you can afford only.
GL
Of the bashers appearing across all boards, all they want to do is continue to sow some seeds of doubt, so that you sell, drop the price and help them buy in at a lower price or gain profit on their shorts.
Ask yourself this question, do you post bashing comments on shares you don’t own? In fact I don’t think I have ever posted on a share I have not owned it about to buy!!! If you think like this, you will realise that they are part of scheme to sow doubt in this share. Happens on every single share, even if the company has just found a billion ounces of gold, they will twist the news in attempt to gain for themselves.
They always seem to appear at the most opportune moments as well haha...when there has been a recent drop. As soon as it goes back up they disappear, same will happen here.
2-3 months of phase 3 read out now, between now and then this will double. After that is anyone’s guess, dependant on how good or not the results are. While this has a good chance of good results due to the drug being used in other areas for many years, as they say nothing is certain in life apart from death!
Follow your own opinion not others, invest what you can afford
GL
https://webcasting.brrmedia.co.uk/broadcast/5d764c88276017390800a4db
Last 3 minutes of this, fun COO talks about being fully funded to complete and also states that the results phase3 will impact some of these funding options.
It doesn’t matter what the results are to be honest, the fact is between now are results day the share price will hit double today’s. Because that’s what happens. It will rise, as it has done already, in anticipation for results, until risk v reward is balanced. Those who hold to results day will either be rewarded heavily or loose money.
No one can tell you if the results will be good or not, even though they have a good chance of passing due to it not being a new drug, tried and tested in other areas. Still no one can tell you.
That’s why, invest what you are happy to loose. From here you should atleast double your money, before results. After that is anyone’s guess only.
Funding is not an issue, If the share price is 30p, or 50p. They will get backers, because the backers will be able to sell them on the rise to results and make a quick profit or if they have deep pockets hold through results and take the gamble/ privy to some of the open label study data maybe. The backers will not loose. This is IF funding even happens before results, which they seemed to state otherwise by saying in the last RNS “the results will heavily impact the funding route taken”.
So if results are good, they will get money from licensing deals. If they decide to go it alone they will still be raising at a much higher price compared to today, minimal dilution.
Make your decision and ignore bulletin boards posters, including me haha. The sell off last week was nervous PIs, nothing more, and we will see more ups and downs along the way. GL
After rereading RNS a few times it still looks like an overreaction to me. In fact there was no new news.
Main points as I see them in the RNS, correct me where I am wrong:
- As of Aug2019, 500 patients had completed the ph3 program. Of these 500, 80% have chosen to continue with open ended study. Two things to highlight here, 1) as of Aug2019 there are still another 500 patients completing their phase 3 program, as remember the study was for 1000 people. 2) of the 500 that completed their phase3, the 80% have continued on in the open ended study are doing so on the full .6% strength because they have to. What I mean by this is the phase 3 study design requires an open ended study to be conducted, where patients can opt to continue, but if so, they must continue on the highest strength only, this is to continue to test the safety of this highest dose.
What this shows is that most patients are choosing to continue, even though it’s at the highest dose! Also if 400 out of the first 500 patient have continued, the company are only 50 patients short of completing the study design requirement for the open ended study. So only 50 out of the next 500 patients are needed, but no doubt it will probably be another 80% take up. It’s says a lot for the safety profile so far and maybe also the gels efficacy...
This is good news
- the ‘biggest negative’ is the high costs, double or triple the same period for 2018. But let’s be honest when running a phase 3 what do people expect? It’s why they raised money in the first place. This should not be a surprise to anyone.
- TPR delay is annoying, but again doesn’t distract from the fact that Med is the main asset and we are still on track for Dec 2019 readout.
- future funding: “including non-dilutory and dilutory options and believe that the results of the FM57 trial will have a major impact on these funding options and the costs associated with them“ - this statement pretty much confirms that once we get results of Med trail then the funding options will be known. Again this is positive as it confirms that there is no funding raise in the short term before Med results in December. If results are good it’s likely to get non diluting funding e.g. licensing deals. if results not good it will be diluting.
Again what did investors expect? They are confirming no funding before results, great news imo. Did any investors think the 2nd phase 3 would be free?
Overall this was a no new news RNS, apart from confirming the higher costs, which is obvious and that 500 out of 1000 patients have completed the trial!!!
I think this has been played hard, wouldn’t be surprised if this is back in the 40s soon. Anything I am missing?
- Spoke with FUM, as surprised as I am at the drop, reiterated that they thought it was good news. Will not write detail on the convo as I am a believer that it’s unfair to the company/person with such Informal discussion, incase of misquoting etc. However no new info dis
Going concern section is always present in results rns for all companies, it’s a requirement!
Very very surprised at the drop, but I shouldn’t be because I have seen it before with other companies in the same position.
Anyway let’s see what happens, I still think this has more legs on the rise, but wtfdik!
Good luck holders
Should be good, everything is indicating an uptrend. Only problem is the wider market, how this is effecting AIM and FUM I am not sure.
I still think upward trend to continue next week. Let’s see....could well be wrong, I am no expert!
GL
Only ~90m, for a company that will have ph3 readout in 3months, for a product with potential billion dollar value.
For this reason it will continue to rise, bar no unforeseen negative news in the next few months, as the risk v reward ratio is still very attractive with the low price.
I have always stated minimum 50p price prior to phase 3 readout, but that’s my conservative target. This is because I believed the company would rise to somewhere between 100m - 200m valuation prior to ph3 readout.
100m = 50p - conservative
150m = 75p - fair
200m = £1 - possible and may only reach it once before falling back, would be very surprised if we got to £1, or close, and stayed there prior to readout.
It’s important to note that these estimates of mine are prices prior to readout, not after, as anything could happen after!!! Up or down dependant on how good or not results are.
At the moment 50p is still cheap, would be happy with 75p!
These are my estimates and all in my opinion. We still have 3 months before readout and this share will only get hotter from increased news, articles and position taking.
GL
My prediction over a week ago of 38-40p possible retrace, from 48p, has hit today. All natural, nothing to worry about, it may even test 35p-ish over the coming week, but again this is all part of the cycle. Hold your nerve it should continue it’s upward trend to the next level at some point. (Timeframes unknown but it’s all short term considering only 4 months until results).
Hi ligumvitae, can you send me a link to where it states they have £53.9 cash as at April? I have been looking for such info and can not find?
Thanks
Can anyone tell me how much cash they have?
They seem to burn through a hell of a lot per year! Looks like a big raise/ dilution is needed???
Thanks guys, so Chronocort missed the ph3 end point, so I guess another phase 3 is required in eu?
Also the talk of Chronocort deals in us, if it failed in eu, why so sure hitting a deal in us? Seems unlikely if it already failed once?
Only came across this recently, so excuse any misunderstanding, if you could help with the answer that would be great:
1) Chronocort, has there been any confirmation as to when the US ph3 will start? Has recruitment begin yet or no? A link would be great if possible.
2) why was the cash raised for exactly? To fund what specifically?
3) with only 10-11m in cash, is this enough to pay for Alkindi manufacturing and marketing, but most importantly is it enough to find the Chronocort US ph3 trails? Trails are costly, does anyone have any info where the company have confirmed they have enough.
My main concern is not the products, they seem to have legs, but another cash raise to fund the above. As would mean more dilution and an obvious drop in share price.